Symptom Management in Patients on Dialysis

Condition(s) studied

Investigational drug(s) / intervention(s)

SUPPORT-DIALYSIS with Access to Output Report and Information Hub: SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team. Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals.

SUPPORT-DIALYSIS Only: SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.

Study summary

This is a parallel arm, pilot study used to examine the feasibility of electronic patient reported outcome measures (ePROMs) for symptom assessment and monitoring as well as a linked self-management support and decision support information hub (https://symptomcare.org) to facilitate symptom management for patients on maintenance hemodialysis.

Two dialysis centers will be included in the study, with one center receiving SUPPORT-Dialysis (intervention arm) and the other receiving standard care (control arm).

Eligibility

Primary outcome measure(s)

• Recruitment Target — Baseline
  Feasibility of toolkit will be confirmed if recruitment target of 30 participants at each site are obtained in a 3-month period of the pilot.
• Proportion of Eligible Patients who decline consent — Baseline
  Feasibility of toolkit will be confirmed if decline rate is \<50% for eligible patients.
• Proportion of Participants who miss or refuse ePROMs follow-ups — Baseline to follow-up (6 months)
  Feasibility of toolkit will be confirmed if \<30% of participants complete \<50% of all follow-up visits.
• Proportion of Enrolled Patients who Drop-Out From the Study — Baseline to follow-up (6 months)
  Feasibility of toolkit will be confirmed if the dropout rate is \< 30%.

Trial sites (2)

More University Health Network, Toronto trials in Canada

Other trials for the same condition